{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "18", "@year": "2020", "@timestamp": "2020-01-18T03:25:10.000010-05:00", "@month": "01"}, "ait:date-sort": {"@day": "01", "@year": "2017", "@month": "01"}}, "xocs:meta": {"xocs:funding-list": {"@pui-match": "primary", "@has-funding-info": "1", "xocs:funding": [{"xocs:funding-agency-matched-string": "Ratcha-daphiseksomphot Endowment Fund"}, {"xocs:funding-agency-matched-string": "Faculty of Medicine, Chulalongkorn University", "xocs:funding-agency": "Faculty of Medicine, Chulalongkorn University", "xocs:funding-agency-id": "http://data.elsevier.com/vocabulary/SciValFunders/501100004776", "xocs:funding-agency-country": "http://sws.geonames.org/1605651/"}], "xocs:funding-addon-generated-timestamp": "2021-02-02T16:04:51.662850Z", "xocs:funding-text": "The study was supported by the Ratcha-daphiseksomphot Endowment Fund, Faculty of Medicine, Chulalongkorn University, Thailand. The authors wish to thank Chula Clinical Research Center and Clinical Pharmacokinetics Research Unit, Faculty of Medicine, Chulalongkorn University.", "xocs:funding-addon-type": "http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/aggregated-refined"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"country": "Thailand", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Chula Pharmacokinetic Research Center"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "119708443"}, "@dptid": "119708443"}, "author": [{"ce:given-name": "Nantaporn", "preferred-name": {"ce:given-name": "Nantaporn", "ce:initials": "N.", "ce:surname": "Prompila", "ce:indexed-name": "Prompila N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Prompila", "@auid": "15846832700", "ce:indexed-name": "Prompila N."}, {"ce:given-name": "Wanna", "preferred-name": {"ce:given-name": "Wanna", "ce:initials": "W.", "ce:surname": "Eiamart", "ce:indexed-name": "Eiamart W."}, "@seq": "2", "ce:initials": "W.", "@_fa": "true", "@type": "auth", "ce:surname": "Eiamart", "@auid": "56156546300", "ce:indexed-name": "Eiamart W."}, {"ce:given-name": "Yaowatree", "preferred-name": {"ce:given-name": "Yaowatree", "ce:initials": "Y.", "ce:surname": "Jumroen", "ce:indexed-name": "Jumroen Y."}, "@seq": "3", "ce:initials": "Y.", "@_fa": "true", "@type": "auth", "ce:surname": "Jumroen", "@auid": "57196298056", "ce:indexed-name": "Jumroen Y."}, {"ce:given-name": "Nonlanee", "preferred-name": {"ce:given-name": "Nonlanee", "ce:initials": "N.", "ce:surname": "Sayankuldilok", "ce:indexed-name": "Sayankuldilok N."}, "@seq": "4", "ce:initials": "N.", "@_fa": "true", "@type": "auth", "ce:surname": "Sayankuldilok", "@auid": "55183867000", "ce:indexed-name": "Sayankuldilok N."}]}, {"affiliation": {"country": "Thailand", "postal-code": "10330", "@afid": "60028190", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pharmacology"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}], "affiliation-id": {"@afid": "60028190", "@dptid": "104425668"}, "@dptid": "104425668"}, "author": [{"ce:given-name": "Pajaree", "preferred-name": {"ce:given-name": "Pajaree", "ce:initials": "P.", "ce:surname": "Chariyavilaskul", "ce:indexed-name": "Chariyavilaskul P."}, "@seq": "5", "ce:initials": "P.", "@_fa": "true", "@type": "auth", "ce:surname": "Chariyavilaskul", "@auid": "55770175000", "ce:indexed-name": "Chariyavilaskul P."}, {"ce:given-name": "Wannarasami", "preferred-name": {"ce:given-name": "Wannarasami", "ce:initials": "W.", "ce:surname": "Ketchat", "ce:indexed-name": "Ketchat W."}, "@seq": "6", "ce:initials": "W.", "@_fa": "true", "@type": "auth", "ce:surname": "Ketchat", "@auid": "57196299269", "ce:indexed-name": "Ketchat W."}, {"ce:given-name": "Supeecha", "preferred-name": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}, "@seq": "7", "ce:initials": "S.", "@_fa": "true", "@type": "auth", "ce:surname": "Wittayalertpanya", "@auid": "6602827304", "ce:indexed-name": "Wittayalertpanya S."}]}], "citation-title": "Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects", "abstracts": "\u00a92017 Dustri-Verlag Dr. K. Feistle.Objective: The purpose of the study was to evaluate the pharmacokinetics and bioequivalence of pregabalin following administration of a 150-mg capsule of test and reference products. Method: The study was designed as a randomized, two-treatment, two-period, two-sequence, single-dose crossover with 1-week washout period between period I and period II dosing. 20 healthy male and female Thai subjects were enrolled in the study. Each subject was in fasted state for \u223c 10 hours prior to receiving a single oral 150-mg pregabalin capsule. Serial blood samples were collected at pre-dose until 32 hours after drug administration. Plasma samples were extracted by protein precipitation and derivatized with 4-chloro-7-nitrobenzofurazan. Pregabalin plasma concentrations were determined by HPLC method, and pharmacokinetic parameters were calculated. For bioequivalence assessment, the differences of Cmax, AUC0-t, and AUC0-inf means based on ln-transformed data were assessed by the 90% confidence interval (CI). Results: Pharmacokinetic parameters were determined that test and reference products showed 0.96 \u00b1 0.35 and 1.04 \u00b1 0.96 hours for tmax, 4,594.217 \u00b1 834.195 and 4,568.68 \u00b1 573.963 ng/mL for Cmax, 30,048.150 \u00b1 2,998.920 and 29,315.722 \u00b1 2,747.396 ng\u00d7h/mL for AUC0-t, 30,594.210 \u00b1 2,872.317 and 29,831.454 \u00b1 2,688.020 ng\u00d7h/mL for AUC0-inf, respectively. The 90% CIs of Cmax, AUC0-t, and AUC0-inf for test and reference products were assessed at 95.356 - 104.630%, 99.303 - 105.751%, and 99.373 - 105.788%, respectively. The results were within the acceptance criteria of 80 - 125%. Conclusion: Pharmacokinetic parameters of a single oral 150-mg pregabalin capsule in healthy Thai subjects were evaluated and showed rapid absorption. 90% CI for the differences of Cmax, AUC0-t, and AUC0-inf were within the acceptable range of the criteria so that bioequivalence of the test and reference products of pregabalin 150-mg capsule could be concluded.", "correspondence": {"affiliation": {"country": "Thailand", "postal-code": "10330", "@country": "tha", "city": "Bangkok", "organization": [{"$": "Department of Pharmacology"}, {"$": "Faculty of Medicine"}, {"$": "Chulalongkorn University"}]}, "person": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Bioequivalence", "@xml:lang": "eng"}, {"$": "Pharmacokinetics", "@xml:lang": "eng"}, {"$": "Pregabalin", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"website": {"ce:e-address": {"$": "http://www.dustri.com/nc/journals-in-english/mag/int-journal-of-clinical-pharmacology-and-therapeutics.html", "@type": "email"}}, "translated-sourcetitle": {"$": "International Journal of Clinical Pharmacology and Therapeutics", "@xml:lang": "eng"}, "volisspag": {"voliss": {"@volume": "55", "@issue": "10"}, "pagerange": {"@first": "811", "@last": "817"}}, "@type": "j", "sourcetitle": "International Journal of Clinical Pharmacology and Therapeutics", "publicationdate": {"year": "2017", "date-text": {"@xfab-added": "true", "$": "2017"}}, "codencode": "ICTHE", "sourcetitle-abbrev": "Int. J. Clin. Pharmacol. Ther.", "@country": "deu", "issn": {"$": "09461965", "@type": "print"}, "publicationyear": {"@first": "2017"}, "publisher": {"affiliation": {"address-part": "Bajuwarenring 4", "postal-code": "82041", "@country": "deu", "city": "Oberhaching"}, "publishername": "Dustri-Verlag Dr. Karl Feistle", "ce:e-address": {"$": "marina.rottner@dustri.de", "@type": "email"}}, "@srcid": "22434"}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "CABSCLASS", "classification": {"classification-code": "99", "classification-description": "General"}}, {"@type": "EMCLASS", "classification": [{"classification-code": "17", "classification-description": "Public Health, Social Medicine and Epidemiology"}, {"classification-code": "30", "classification-description": "Clinical and Experimental Pharmacology"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}]}, {"@type": "ASJC", "classification": [{"$": "3004"}, {"$": "2736"}]}, {"@type": "SUBJABBR", "classification": [{"$": "PHAR"}, {"$": "MEDI"}]}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "10199-89-0", "chemical-name": "4 chloro 7 nitrobenzofurazan"}, {"cas-registry-number": "148553-50-8", "chemical-name": "pregabalin"}]}, {"@source": "nlm", "chemical": [{"chemical-name": "Capsules"}, {"chemical-name": "Pregabalin"}, {"chemical-name": "Tablets"}]}]}}}, "item-info": {"copyright": {"$": "Copyright 2017 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, "dbcollection": [{"$": "CABS"}, {"$": "EMBASE"}, {"$": "MEDL"}, {"$": "REAXYS"}, {"$": "REAXYSCAR"}, {"$": "RMC"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "14", "@year": "2017", "@timestamp": "BST 16:24:34", "@month": "12"}}, "itemidlist": {"itemid": [{"$": "618982340", "@idtype": "PUI"}, {"$": "2017338024", "@idtype": "CABS"}, {"$": "768202099", "@idtype": "CAR-ID"}, {"$": "20170764148", "@idtype": "EMBASE"}, {"$": "28513426", "@idtype": "MEDL"}, {"$": "2017238779", "@idtype": "REAXYS"}, {"$": "20171913602", "@idtype": "REAXYSCAR"}, {"$": "2017308488", "@idtype": "RMC"}, {"$": "20170832514", "@idtype": "SCOPUS"}, {"$": "85032591455", "@idtype": "SCP"}, {"$": "85032591455", "@idtype": "SGR"}, {"$": "619641033", "@idtype": "PUIsecondary"}], "ce:doi": "10.5414/CP202954"}}, "tail": {"bibliography": {"@refcount": "14", "reference": [{"ref-fulltext": "Bockbrader HN, Wesche D, Miller R, Chapel S, Janiczek N, Burger P. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49: 661-669. CrossRef PubMed", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin"}, "refd-itemidlist": {"itemid": {"$": "77956360935", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "49"}, "pagerange": {"@first": "661", "@last": "669"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.N.", "@_fa": "true", "ce:surname": "Bockbrader", "ce:indexed-name": "Bockbrader H.N."}, {"@seq": "2", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Wesche", "ce:indexed-name": "Wesche D."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Miller", "ce:indexed-name": "Miller R."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Chapel", "ce:indexed-name": "Chapel S."}, {"@seq": "5", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Janiczek", "ce:indexed-name": "Janiczek N."}, {"@seq": "6", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Burger", "ce:indexed-name": "Burger P."}]}, "ref-sourcetitle": "Clin Pharmacokinet."}}, {"ref-fulltext": "Lauria-Horner BA, Pohl RB. Pregabalin: A new anxiolytic. Expert Opin Investig Drugs. 2003; 12: 663-672. CrossRef PubMed", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Pregabalin: A new anxiolytic"}, "refd-itemidlist": {"itemid": {"$": "0037399193", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12"}, "pagerange": {"@first": "663", "@last": "672"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.A.", "@_fa": "true", "ce:surname": "Lauria-Horner", "ce:indexed-name": "Lauria-Horner B.A."}, {"@seq": "2", "ce:initials": "R.B.", "@_fa": "true", "ce:surname": "Pohl", "ce:indexed-name": "Pohl R.B."}]}, "ref-sourcetitle": "Expert Opin Investig Drugs."}}, {"ref-fulltext": "Schulze-Bonhage A. Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy. Expert Opin Drug Metab Toxicol. 2013; 9: 105-115. CrossRef PubMed", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2013"}, "ref-title": {"ref-titletext": "Pharmacokinetic and pharmacodynamic profile of pregabalin and its role in the treatment of epilepsy"}, "refd-itemidlist": {"itemid": {"$": "84871183521", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "9"}, "pagerange": {"@first": "105", "@last": "115"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Schulze-Bonhage", "ce:indexed-name": "Schulze-Bonhage A."}]}, "ref-sourcetitle": "Expert Opin Drug Metab Toxicol."}}, {"ref-fulltext": "Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004; 45 (Suppl 6): 13-18. CrossRef PubMed", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Pregabalin pharmacology and its relevance to clinical practice"}, "refd-itemidlist": {"itemid": {"$": "5344249471", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "45"}, "pagerange": {"@first": "13", "@last": "18"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Ben-Menachem", "ce:indexed-name": "Ben-Menachem E."}]}, "ref-sourcetitle": "Epilepsia."}}, {"ref-fulltext": "Gray P. Pregabalin in the management of central neuropathic pain. Expert Opin Pharmacother. 2007; 8: 3035-3041. CrossRef PubMed", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Pregabalin in the management of central neuropathic pain"}, "refd-itemidlist": {"itemid": {"$": "37349068859", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "8"}, "pagerange": {"@first": "3035", "@last": "3041"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Gray", "ce:indexed-name": "Gray P."}]}, "ref-sourcetitle": "Expert Opin Pharmacother."}}, {"ref-fulltext": "Tjandrawinata RR, Setiawati E, Putri RSI, Gunawan VA, Ong F, Susanto LW, Nofiarny D. Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin. Clin Pharmacol. 2015; 7: 69-75. CrossRef PubMed", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin"}, "refd-itemidlist": {"itemid": {"$": "84930943694", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "7"}, "pagerange": {"@first": "69", "@last": "75"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.R.", "@_fa": "true", "ce:surname": "Tjandrawinata", "ce:indexed-name": "Tjandrawinata R.R."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Setiawati", "ce:indexed-name": "Setiawati E."}, {"@seq": "3", "ce:initials": "R.S.I.", "@_fa": "true", "ce:surname": "Putri", "ce:indexed-name": "Putri R.S.I."}, {"@seq": "4", "ce:initials": "V.A.", "@_fa": "true", "ce:surname": "Gunawan", "ce:indexed-name": "Gunawan V.A."}, {"@seq": "5", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Ong", "ce:indexed-name": "Ong F."}, {"@seq": "6", "ce:initials": "L.W.", "@_fa": "true", "ce:surname": "Susanto", "ce:indexed-name": "Susanto L.W."}, {"@seq": "7", "ce:initials": "D.", "@_fa": "true", "ce:surname": "Nofiarny", "ce:indexed-name": "Nofiarny D."}]}, "ref-sourcetitle": "Clin Pharmacol."}}, {"ref-fulltext": "Toth C. Pregabalin: Latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014; 5: 38-56. CrossRef PubMed", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "ref-title": {"ref-titletext": "Pregabalin: Latest safety evidence and clinical implications for the management of neuropathic pain"}, "refd-itemidlist": {"itemid": {"$": "84898906370", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5"}, "pagerange": {"@first": "38", "@last": "56"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Toth", "ce:indexed-name": "Toth C."}]}, "ref-sourcetitle": "Ther Adv Drug Saf."}}, {"ref-fulltext": "Filipe A, Almeida S, Pedroso PF, Neves R, Marques S, Sicard E, Massicotte J, Ortu\u00f1o J. Single-dose, randomized, open-label, two-way, crossover bioequivalence study of two formulations of regabalin 300 mg hard capsules in healthy volunteers under fasting conditions. Drugs R D. 2015; 15: 195-201. CrossRef PubMed", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2015"}, "ref-title": {"ref-titletext": "Single-dose, randomized, open-label, two-way, crossover bioequivalence study of two formulations of regabalin 300 mg hard capsules in healthy volunteers under fasting conditions"}, "refd-itemidlist": {"itemid": {"$": "84973274611", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15"}, "pagerange": {"@first": "195", "@last": "201"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Filipe", "ce:indexed-name": "Filipe A."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Almeida", "ce:indexed-name": "Almeida S."}, {"@seq": "3", "ce:initials": "P.F.", "@_fa": "true", "ce:surname": "Pedroso", "ce:indexed-name": "Pedroso P.F."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Neves", "ce:indexed-name": "Neves R."}, {"@seq": "5", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Marques", "ce:indexed-name": "Marques S."}, {"@seq": "6", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Sicard", "ce:indexed-name": "Sicard E."}, {"@seq": "7", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Massicotte", "ce:indexed-name": "Massicotte J."}, {"@seq": "8", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Ortu\u00f1o", "ce:indexed-name": "Ortuno J."}]}, "ref-sourcetitle": "Drugs R D."}}, {"ref-fulltext": "ASEAN Guideline for the Conduct of Bioequivalence studies. Draft 4; 2014: June.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2014"}, "refd-itemidlist": {"itemid": {"$": "85032573165", "@idtype": "SGR"}}, "ref-text": "Draft 4;: June.", "ref-sourcetitle": "ASEAN Guideline for the Conduct of Bioequivalence Studies"}}, {"ref-fulltext": "Onal A, Sagirli O. Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation. Spectrochim Acta A Mol Biomol Spectrosc. 2009; 72: 68-71. CrossRef PubMed", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Spectrophotometric and spectrofluorimetric methods for the determination of pregabalin in bulk and pharmaceutical preparation"}, "refd-itemidlist": {"itemid": {"$": "57949098131", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "72"}, "pagerange": {"@first": "68", "@last": "71"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Onal", "ce:indexed-name": "Onal A."}, {"@seq": "2", "ce:initials": "O.", "@_fa": "true", "ce:surname": "Sagirli", "ce:indexed-name": "Sagirli O."}]}, "ref-sourcetitle": "Spectrochim Acta A Mol Biomol Spectrosc."}}, {"ref-fulltext": "U.S. Department of Health and Human Services, FDA. Guidance for Industry-Bioanalytical method validation. U.S. Department of Health and Human Services, FDA, CDER, CVM 2001; May.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "refd-itemidlist": {"itemid": {"$": "0003484310", "@idtype": "SGR"}}, "ref-text": "U.S. Department of Health and Human Services, FDA. U.S. Department of Health and Human Services, FDA, CDER, CVM; May.", "ref-sourcetitle": "Guidance for Industry-Bioanalytical Method Validation"}}, {"ref-fulltext": "European Medicines Agency. Guideline on bioanalytical method validation. European Medicines Agency. Science Medicine Health. Committee for Medicinal Products for Human Use (CHMP) 2011; July.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "2011"}, "refd-itemidlist": {"itemid": {"$": "81055146012", "@idtype": "SGR"}}, "ref-text": "European Medicines Agency. European Medicines Agency. Science Medicine Health. Committee for Medicinal Products for Human Use (CHMP); July.", "ref-sourcetitle": "Guideline on Bioanalytical Method Validation"}}, {"ref-fulltext": "Zaid AN, Kittana N, Mousa A, Ghazal N, Bustami R. Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers. Int J Clin Pharmacol Ther. 2016; 54: 723- 731. CrossRef PubMed", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Bioequivalence assessment of two pregabalin capsules in healthy Mediterranean Arab volunteers"}, "refd-itemidlist": {"itemid": {"$": "84984670056", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "54"}, "pagerange": {"@first": "723", "@last": "731"}}, "ref-text": "CrossRef PubMed", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.N.", "@_fa": "true", "ce:surname": "Zaid", "ce:indexed-name": "Zaid A.N."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Kittana", "ce:indexed-name": "Kittana N."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Mousa", "ce:indexed-name": "Mousa A."}, {"@seq": "4", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Ghazal", "ce:indexed-name": "Ghazal N."}, {"@seq": "5", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Bustami", "ce:indexed-name": "Bustami R."}]}, "ref-sourcetitle": "Int J Clin Pharmacol Ther."}}, {"ref-fulltext": "Rosete-Reyes A, Mendoza-Tamayo G, Lopez-Bojorquez E, Burke-Frage V, Gonzalez-de PM. Bioequivalence study of two oral-capsule formulations of pregabalin 300 mg in healthy Mexican adult. J Bioequiv. 2016; 2: 101-106.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2016"}, "ref-title": {"ref-titletext": "Bioequivalence study of two oral-capsule formulations of pregabalin 300 mg in healthy Mexican adult"}, "refd-itemidlist": {"itemid": {"$": "85032571589", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "2"}, "pagerange": {"@first": "101", "@last": "106"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Rosete-Reyes", "ce:indexed-name": "Rosete-Reyes A."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Mendoza-Tamayo", "ce:indexed-name": "Mendoza-Tamayo G."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Lopez-Bojorquez", "ce:indexed-name": "Lopez-Bojorquez E."}, {"@seq": "4", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Burke-Frage", "ce:indexed-name": "Burke-Frage V."}, {"@seq": "5", "ce:initials": "P.M.", "@_fa": "true", "ce:surname": "Gonzalez-De", "ce:indexed-name": "Gonzalez-De P.M."}]}, "ref-sourcetitle": "J Bioequiv."}}]}}}}, "affiliation": {"affiliation-city": "Bangkok", "@id": "60028190", "affilname": "Chulalongkorn University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190", "affiliation-country": "Thailand"}, "coredata": {"srctype": "j", "eid": "2-s2.0-85032591455", "dc:description": "Objective: The purpose of the study was to evaluate the pharmacokinetics and bioequivalence of pregabalin following administration of a 150-mg capsule of test and reference products. Method: The study was designed as a randomized, two-treatment, two-period, two-sequence, single-dose crossover with 1-week washout period between period I and period II dosing. 20 healthy male and female Thai subjects were enrolled in the study. Each subject was in fasted state for \u223c 10 hours prior to receiving a single oral 150-mg pregabalin capsule. Serial blood samples were collected at pre-dose until 32 hours after drug administration. Plasma samples were extracted by protein precipitation and derivatized with 4-chloro-7-nitrobenzofurazan. Pregabalin plasma concentrations were determined by HPLC method, and pharmacokinetic parameters were calculated. For bioequivalence assessment, the differences of Cmax, AUC0-t, and AUC0-inf means based on ln-transformed data were assessed by the 90% confidence interval (CI). Results: Pharmacokinetic parameters were determined that test and reference products showed 0.96 \u00b1 0.35 and 1.04 \u00b1 0.96 hours for tmax, 4,594.217 \u00b1 834.195 and 4,568.68 \u00b1 573.963 ng/mL for Cmax, 30,048.150 \u00b1 2,998.920 and 29,315.722 \u00b1 2,747.396 ng\u00d7h/mL for AUC0-t, 30,594.210 \u00b1 2,872.317 and 29,831.454 \u00b1 2,688.020 ng\u00d7h/mL for AUC0-inf, respectively. The 90% CIs of Cmax, AUC0-t, and AUC0-inf for test and reference products were assessed at 95.356 - 104.630%, 99.303 - 105.751%, and 99.373 - 105.788%, respectively. The results were within the acceptance criteria of 80 - 125%. Conclusion: Pharmacokinetic parameters of a single oral 150-mg pregabalin capsule in healthy Thai subjects were evaluated and showed rapid absorption. 90% CI for the differences of Cmax, AUC0-t, and AUC0-inf were within the acceptable range of the criteria so that bioequivalence of the test and reference products of pregabalin 150-mg capsule could be concluded.", "pubmed-id": "28513426", "prism:coverDate": "2017-01-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/85032591455", "dc:creator": {"author": [{"ce:given-name": "Nantaporn", "preferred-name": {"ce:given-name": "Nantaporn", "ce:initials": "N.", "ce:surname": "Prompila", "ce:indexed-name": "Prompila N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Prompila", "@auid": "15846832700", "author-url": "https://api.elsevier.com/content/author/author_id/15846832700", "ce:indexed-name": "Prompila N."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/85032591455"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85032591455&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85032591455&origin=inward"}], "source-id": "22434", "citedby-count": "0", "prism:volume": "55", "subtype": "ar", "dc:title": "Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects", "openaccess": "0", "prism:issn": "09461965", "publishercopyright": "\u00a92017 Dustri-Verlag Dr. K. Feistle.", "prism:issueIdentifier": "10", "subtypeDescription": "Article", "prism:publicationName": "International Journal of Clinical Pharmacology and Therapeutics", "prism:pageRange": "811-817", "prism:endingPage": "817", "openaccessFlag": "false", "prism:doi": "10.5414/CP202954", "prism:startingPage": "811", "dc:identifier": "SCOPUS_ID:85032591455", "dc:publisher": "Dustri-Verlag Dr. Karl FeistleBajuwarenring 4Oberhaching82041marina.rottner@dustri.de"}, "idxterms": {"mainterm": [{"$": "Administration, Oral", "@weight": "b", "@candidate": "n"}, {"$": "Adolescent", "@weight": "b", "@candidate": "n"}, {"$": "Adult", "@weight": "b", "@candidate": "n"}, {"$": "Area Under Curve", "@weight": "b", "@candidate": "n"}, {"$": "Biological Availability", "@weight": "b", "@candidate": "n"}, {"$": "Capsules", "@weight": "b", "@candidate": "n"}, {"$": "Cross-Over Studies", "@weight": "b", "@candidate": "n"}, {"$": "Female", "@weight": "b", "@candidate": "n"}, {"$": "Half-Life", "@weight": "b", "@candidate": "n"}, {"$": "Healthy Volunteers", "@weight": "b", "@candidate": "n"}, {"$": "Humans", "@weight": "b", "@candidate": "n"}, {"$": "Male", "@weight": "b", "@candidate": "n"}, {"$": "Middle Aged", "@weight": "b", "@candidate": "n"}, {"$": "Pregabalin", "@weight": "b", "@candidate": "n"}, {"$": "Tablets", "@weight": "b", "@candidate": "n"}, {"$": "Thailand", "@weight": "b", "@candidate": "n"}, {"$": "Therapeutic Equivalency", "@weight": "b", "@candidate": "n"}, {"$": "Young Adult", "@weight": "b", "@candidate": "n"}]}, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Bioequivalence"}, {"@_fa": "true", "$": "Pharmacokinetics"}, {"@_fa": "true", "$": "Pregabalin"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Pharmacology", "@code": "3004", "@abbrev": "PHAR"}, {"@_fa": "true", "$": "Pharmacology (medical)", "@code": "2736", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Nantaporn", "preferred-name": {"ce:given-name": "Nantaporn", "ce:initials": "N.", "ce:surname": "Prompila", "ce:indexed-name": "Prompila N."}, "@seq": "1", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Prompila", "@auid": "15846832700", "author-url": "https://api.elsevier.com/content/author/author_id/15846832700", "ce:indexed-name": "Prompila N."}, {"ce:given-name": "Wanna", "preferred-name": {"ce:given-name": "Wanna", "ce:initials": "W.", "ce:surname": "Eiamart", "ce:indexed-name": "Eiamart W."}, "@seq": "2", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Eiamart", "@auid": "56156546300", "author-url": "https://api.elsevier.com/content/author/author_id/56156546300", "ce:indexed-name": "Eiamart W."}, {"ce:given-name": "Yaowatree", "preferred-name": {"ce:given-name": "Yaowatree", "ce:initials": "Y.", "ce:surname": "Jumroen", "ce:indexed-name": "Jumroen Y."}, "@seq": "3", "ce:initials": "Y.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Jumroen", "@auid": "57196298056", "author-url": "https://api.elsevier.com/content/author/author_id/57196298056", "ce:indexed-name": "Jumroen Y."}, {"ce:given-name": "Nonlanee", "preferred-name": {"ce:given-name": "Nonlanee", "ce:initials": "N.", "ce:surname": "Sayankuldilok", "ce:indexed-name": "Sayankuldilok N."}, "@seq": "4", "ce:initials": "N.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Sayankuldilok", "@auid": "55183867000", "author-url": "https://api.elsevier.com/content/author/author_id/55183867000", "ce:indexed-name": "Sayankuldilok N."}, {"ce:given-name": "Pajaree", "preferred-name": {"ce:given-name": "Pajaree", "ce:initials": "P.", "ce:surname": "Chariyavilaskul", "ce:indexed-name": "Chariyavilaskul P."}, "@seq": "5", "ce:initials": "P.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Chariyavilaskul", "@auid": "55770175000", "author-url": "https://api.elsevier.com/content/author/author_id/55770175000", "ce:indexed-name": "Chariyavilaskul P."}, {"ce:given-name": "Wannarasami", "preferred-name": {"ce:given-name": "Wannarasami", "ce:initials": "W.", "ce:surname": "Ketchat", "ce:indexed-name": "Ketchat W."}, "@seq": "6", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Ketchat", "@auid": "57196299269", "author-url": "https://api.elsevier.com/content/author/author_id/57196299269", "ce:indexed-name": "Ketchat W."}, {"ce:given-name": "Supeecha", "preferred-name": {"ce:given-name": "Supeecha", "ce:initials": "S.", "ce:surname": "Wittayalertpanya", "ce:indexed-name": "Wittayalertpanya S."}, "@seq": "7", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60028190", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190"}, "ce:surname": "Wittayalertpanya", "@auid": "6602827304", "author-url": "https://api.elsevier.com/content/author/author_id/6602827304", "ce:indexed-name": "Wittayalertpanya S."}]}}}